TP53 and diffuse large B-cell lymphoma: Importantly, only p53 mutations, which are found in about 20% of DLBCL, appear to be associated with clinical drug resistance and poor outcome (Villuendas et al. 1993; Piris et al. 1994; Kramer et al. 1996; Ichikawa et al. 1997; Koduru et al. 1997; Wilson et al. 1997; Moller et al. 1999; Llanos et al. 2001; Leroy et al. 2002; Kerbauy et al. 2004).